- Karen Hussmann, Independent Expert and Researcher, U4 Anti-Corruption Resource Centre
- Priya Basu, Head of the Secretariat of the Multilateral Leaders Taskforce on COVID-19, The World Bank Group
- Eduardo Bohórquez, Executive Director, Transparency International Mexico
- Paul Richard Fife, Director, Department for Human Development, Norwegian Agency for Development Cooperation
- Charles Kenny, Senior Fellow, Center for Global Development
- Arne Strand, Director, U4 Anti-Corruption Resource Centre
- Javier Guzman, Director of the Global Health Policy Program and Senior Policy Fellow, Center for Global Development
ABOUT THE EVENT
After earlier calls for transparency in the global deployment of COVID-19 vaccine, we’ve seen progress: in addition to UNICEF’s COVID-19 Vaccine Dashboard launched in December 2020, the Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics – launched in June 2021 – houses a central repository with (partial) data on vaccine purchasing and deployment; (some) governments have released (few) contract details; and (select) manufacturers have contributed their designs to technology transfer hubs to facilitate the scale-up of production. But these steps have been small and limited. The overwhelming lack of information on COVID-19 vaccine research and development, manufacturing, contracts, and deployment in the public domain still leads to unpredictable delivery times, wasted doses, high purchasing prices in low- and middle-income countries, and inequitable distribution.
Join the Center for Global Development and the U4 Anti-Corruption Resource Centre for a virtual discussion on the progress and challenges in the transparent deployment of COVID-19 vaccine, building on recent recommendations from U4 on next steps for greater transparency. Speakers will highlight the importance of transparency in the current moment of the COVID-19 crisis, when equitable distribution surpasses supply as the most pressing challenge. The panel will also discuss topics including possible mechanisms of accountability for manufacturers and procurers and how governments and global COVID-19 vaccine procurement mechanisms should balance public and private interests.